{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:47:26Z","timestamp":1790596046905,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010945","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000}}],"reference-count":142,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010945.pub2","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T23:45:09Z","timestamp":1613000709000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting"],"prefix":"10.1002","volume":"2021","author":[{"given":"Michelle","family":"Kokkinou","sequence":"additional","affiliation":[{"name":"MRC London Institute of Medical Sciences; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C","family":"Beishon","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences; University of Leicester; Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Smailagic","sequence":"additional","affiliation":[{"name":"Institute of Public Health; University of Cambridge ; Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H","family":"Noel-Storr","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine; University of Oxford ; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hyde","sequence":"additional","affiliation":[{"name":"Exeter Test Group; College of Medicine and Health, University of Exeter Medical School, University of Exeter; Exeter  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obioha","family":"Ukoumunne","sequence":"additional","affiliation":[{"name":"NIHR CLAHRC South West Peninsula (PenCLAHRC); University of Exeter Medical School; Exeter UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary E","family":"Worrall","sequence":"additional","affiliation":[{"name":"University of Oxford Medical School; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Hayen","sequence":"additional","affiliation":[{"name":"Department of Psychology and Clinical Language Sciences; University of Reading; Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Experimental Psychology; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishekh Hulegar","family":"Ashok","sequence":"additional","affiliation":[{"name":"MRC London Institute of Medical Sciences; Imperial College London; London UK"},{"name":"Department of Psychosis Studies; Institute of Psychiatry, Psychology and Neuroscience, King's College ; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor J","family":"Paul","sequence":"additional","affiliation":[{"name":"MRC London Institute of Medical Sciences; Imperial College London; London UK"},{"name":"Institute of Clinical Sciences (ICS), Faculty of Medicine; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Georgopoulou","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Casoli","sequence":"additional","affiliation":[{"name":"Center for Neurobiology of Aging; IRCCS INRCA; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J","family":"Quinn","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences; University of Glasgow; Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences; University of Edinburgh; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"10.1002\/14651858.CD010945.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3233\/JAD-180409","article-title":"Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study","volume":"66","author":"Abu-Rumeileh","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-2011-110482","article-title":"CSF tau, A\u03b242 and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease","volume":"27","author":"Aerts","year":"2011","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1-2","key":"10.1002\/14651858.CD010945.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jns.2015.09.022","article-title":"Cerebrospinal fluid A\u03b240 is similarly reduced in patients with frontotemporal lobar degeneration and Alzheimer's disease","volume":"358","author":"Baldeiras","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD010945.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00702-006-0537-z","article-title":"CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies","volume":"113","author":"Bibl","year":"2006","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00702-006-0618-z","article-title":"Reduced CSF carboxyterminally truncated A\u03b2 peptides in frontotemporal lobe degenerations","volume":"114","author":"Bibl","year":"2007","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3233\/JAD-150731","article-title":"Diagnstic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau, A\u03b242, and A\u03b240) in prodromal stage of Alzheimer's disease and dementia with Lewy bodies","volume":"51","author":"Bousiges","year":"2016","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2017-316385","article-title":"Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease at the prodromal stage","volume":"89","author":"Bousiges","year":"2018","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000091436","article-title":"The neuro\ufb01lament heavy chain (NfH SMI35 ) in the cerebrospinal fluid diagnosis of Alzheimer\u2019s disease","volume":"21","author":"Brettschneider","year":"2006","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1177\/0300060519860951","article-title":"Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer\u2019s disease","volume":"47","author":"Casoli","year":"2019","journal-title":"Journal of International Medical Research"},{"issue":"7","key":"10.1002\/14651858.CD010945.pub2-BIB0010|cit10","first-page":"755","article-title":"Cerebrospinal fluid amyloid \u03b242 \/ phosphorelated tau ratio discriminates between Alzheimer's disease and vascular dementia","volume":"61A","author":"Jong","year":"2006","journal-title":"Journal of Gerontology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10072-011-0866-z","article-title":"CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia","volume":"33","author":"Rino","year":"2012","journal-title":"Neurological Sciences"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/hbm.24925","article-title":"Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures","volume":"41","author":"Falgas","year":"2020","journal-title":"Human Brain Mapping"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jalz.2013.05.1775","article-title":"Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias","volume":"10","author":"Herbert","year":"2014","journal-title":"Alzheimer's and Dementia"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jnnp.71.3.401","article-title":"Highly increased CSF tau protein and decreased \u03b2-amyloid1-42 in sporadic CJD: a discrimination from Alzheimer's disease?","volume":"71","author":"Kapaki","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010945.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1468-1331.2003.00562.x","article-title":"CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population","volume":"10","author":"Kapaki","year":"2003","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/gps.1351","article-title":"The diagnostic value of tau protein, \u03b2-amyloid1-42 and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages","volume":"20","author":"Kapaki","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010945.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1468-1331.2006.01593.x","article-title":"Cerebrospinal fluid tau, phospho-tau181 and b-amyloid1)42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer\u2019s disease","volume":"14","author":"Kapaki","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010945.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WAD.0b013e3181610fea","article-title":"Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration","volume":"22","author":"Kapaki","year":"2008","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3233\/JAD-180855","article-title":"Improved differential diagnosis of Alzheimer\u2019s disease by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers","volume":"67","author":"Khoonsari","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/WAD.0000000000000268","article-title":"The effect of changing the amyloid \u03b242 cut-off of cerebrospinal fluid biomarkers on Alzheimer disease diagnosis in a memory clinic population in Norway","volume":"33","author":"Knapskog","year":"2019","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"273-281","DOI":"10.1016\/S0197-4580(03)00086-1","article-title":"Neurochemical diagnosis of Alzheimer\u2019s dementia by CSF A42, A42\/A40 ratio and total tau","volume":"25","author":"Lewczuk","year":"2004","journal-title":"Neurobiology of Aging"},{"issue":"3","key":"10.1002\/14651858.CD010945.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-003-0075-x","article-title":"Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus","volume":"111","author":"Lins","year":"2004","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s10072-018-3400-8","article-title":"Biomarkers study in atypical dementia: proof of a diagnostic work-up","volume":"39","author":"Lombardi","year":"2018","journal-title":"Neurological Sciences"},{"issue":"9","key":"10.1002\/14651858.CD010945.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/archneur.60.9.1202","article-title":"Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide 42","volume":"60","author":"Maddalena","year":"2003","journal-title":"Archives of Neurology."},{"key":"10.1002\/14651858.CD010945.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.18632\/aging.101925","article-title":"Diagnostic performance of new and classic CSF biomarkers in age-related dementias","volume":"11","author":"Marchegiani","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","article-title":"Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls","volume":"125","author":"Montine","year":"2001","journal-title":"Archives of Pathology and Laboratory Medicine."},{"key":"10.1002\/14651858.CD010945.pub2-BIB0027|cit27","first-page":"205","article-title":"CSF biomarker profile and diagnostic value in vascular dementia","volume":"2","author":"Paraskevas","journal-title":"European Journal of Neurology."},{"issue":"3","key":"10.1002\/14651858.CD010945.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00259-015-3170-y","article-title":"Cross-validation of biomarkers to early differential diagnosis and prognosis of dementia in a clinical setting","volume":"43","author":"Perani","year":"2015","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"2","key":"10.1002\/14651858.CD010945.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s007020170091","article-title":"Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of alzheimer's disease patients","volume":"108","author":"Rosler","journal-title":"Journal of Neural Transmission."},{"key":"10.1002\/14651858.CD010945.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-170186","article-title":"Cerebrospinal fluid amyloid-\u03b2 42, total tau and phosphorylated tau are low in patients with normal pressure hydrocephalus: analogies and differences with Alzheimer's disease","volume":"60","author":"Santangelo","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"issue":"86","key":"10.1002\/14651858.CD010945.pub2-BIB0031|cit31","article-title":"A clinical and biochemical analysis in the differential diagnosis of idiopathic normalpressure hydrocephalus","volume":"6","author":"Schirinzi","year":"2015","journal-title":"Frontiers in Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jalz.2018.02.015","article-title":"CSF \u03b1-synuclein contributes to the differential diagnosis of Alzheimer disease","volume":"14","author":"Shi","year":"2018","journal-title":"Alzheimers Dementia"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, beta-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sjogren","year":"2000","journal-title":"Journal of Neural Transmission."},{"key":"10.1002\/14651858.CD010945.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neulet.2008.05.076","article-title":"CSF -amyloid 1-42 and tau in Tunisian patients with Alzheimer\u2019s disease: The effect of APOE 4 allele","volume":"440","author":"Smacha","year":"2008","journal-title":"Neuroscience Letters"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720510791383796","article-title":"The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia","volume":"7","author":"Spies","year":"2010","journal-title":"Current Alzheimer Research"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2005.05.016","article-title":"AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis","volume":"237","author":"Stefani","year":"2005","journal-title":"Journal of the Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0197-4580(00)00164-0","article-title":"Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease","volume":"21","author":"Tapiola","year":"2000","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3233\/JAD-180548","article-title":"Clinical experience with cerebrospinal fluid A\u03b242, total and phosphorylated tau in the evaluation of 1,016 individuals for suspected dementia","volume":"65","author":"Tariciotti","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ana.10661","article-title":"\u03b2-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"54","author":"Wiltfang","year":"2003","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010945.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-140240","article-title":"Relationship between beta-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease","volume":"42","author":"Alcolea","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"issue":"2","key":"10.1002\/14651858.CD010945.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1212\/WNL.0000000000004088","article-title":"CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration","volume":"89","author":"Alcolea","year":"2017","journal-title":"American Academy of Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3233\/JAD-132195","article-title":"Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment","volume":"40","author":"Balasa","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0043|cit43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147319","article-title":"An Alzheimer's disease-derived biomarker signature identifies Parkinson's disease patients with dementia","volume":"11","author":"Berlyand","year":"2016","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0044|cit44","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-016-0233-7","article-title":"Unbiased estimates of cerebrospinal fluid beta-amyloid 1-42 cutoffs in a large memory clinic population","volume":"9","author":"Bertens","year":"2017","journal-title":"Alzheimer's Research and Therapy"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1471-4159.2007.04763.x","article-title":"Blood-based neurochemical diagnosis of vascular dementia: a pilot study","volume":"103","author":"Bibl","year":"2007","journal-title":"Journal of Neurochemistry"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/prca.200800006","article-title":"CSF amyloid-\u03b2 1-38 and 1-4 2in FTD and AD: biomarker performance critically depends on the detergent accessible fraction","volume":"2","author":"Bibl","year":"2008","journal-title":"Proteomics - Clinical Applications"},{"issue":"6","key":"10.1002\/14651858.CD010945.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1159\/000137534","article-title":"Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic","volume":"25","author":"Brandt","year":"2008","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0048|cit48","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0543-7","article-title":"Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes","volume":"11","author":"Carandini","year":"2019","journal-title":"Alzheimer's Research and Therapy"},{"issue":"11","key":"10.1002\/14651858.CD010945.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jalz.2017.11.015","article-title":"Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: abeta1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40","volume":"14","author":"Hampel","year":"2018","journal-title":"Alzheimer's and Dementia"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neulet.2012.03.094","article-title":"Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease","volume":"516","author":"Han","year":"2012","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/acn3.50948","article-title":"APP-derived peptides reflect neurodegeneration in frontotemporal dementia","volume":"6","author":"Illan-Gala","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010945.pub2-BIB0053|cit53","first-page":"1","article-title":"Biomarkers of Alzheimer's disease and vascular dementia simultaneously sampled from serum and cerebrospinal fluid","volume":"20","author":"Karadas","year":"2017","journal-title":"Turkish Journal of Geriatrics"},{"issue":"8","key":"10.1002\/14651858.CD010945.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/mds.23670","article-title":"Cerebrospinal fluid tau\/a-Synuclein ratio in Parkinson\u2019s disease and degenerative dementias","volume":"26","author":"Parnetti","year":"2011","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2014.05.052","article-title":"Tau protein, beta-amyloid 1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia","volume":"343","author":"Prikrylova Vranova","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/brain\/awv181","article-title":"Cerebrospinal fluid tau and amyloid -\u03b21-42 in patients with dementia","volume":"138","author":"Skillback","year":"2015","journal-title":"Brain"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0057|cit57","first-page":"531","article-title":"Interest of CSF -amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer\u2019s disease","volume":"66","author":"Smach","year":"2008","journal-title":"Annales de Biologie Clinique"},{"issue":"170","key":"10.1002\/14651858.CD010945.pub2-BIB0058|cit58","article-title":"Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis","volume":"11","author":"Stoeck","year":"2014","journal-title":"Journal of Neuroinflammation"},{"issue":"1","key":"10.1002\/14651858.CD010945.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00401-012-0983-7","article-title":"CSF biomarkers cutoffs: the importance of coincident neuropathological disaease","volume":"124","author":"Toledo","year":"2012","journal-title":"Acta Neuropathologica"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s11064-012-0750-0","article-title":"Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia","volume":"37","author":"Uslu","year":"2012","journal-title":"Neurochemical Research"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"Alpha-synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies","volume":"33","author":"Steenoven","year":"2018","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/ijms20194674","article-title":"VGF peptides in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"20","author":"Steenoven","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s10072-017-3053-z","article-title":"A single centre study: A\u03b242\/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting","volume":"38","author":"Vergallo","year":"2017","journal-title":"Neurological Sciences"},{"issue":"63","key":"10.1002\/14651858.CD010945.pub2-BIB0064|cit64","article-title":"Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients","volume":"7","author":"Wennstrom","year":"2015","journal-title":"Alzheimer's Research and Therapy"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-132561","article-title":"Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort","volume":"41","author":"Zwan","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"issue":"3","key":"10.1002\/14651858.CD010945.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendation from the National Institute on Ageing and Alzheimer's Association workgroup","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0067|cit67","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 3rd revised edition American Psychiatric Association 1987"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0068|cit68","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th edition American Psychiatric Association 1994"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0069|cit69","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th edition (revised) American Psychiatric Association, Washington, DC 2000"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0070|cit70","doi-asserted-by":"crossref","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer's disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010","volume":"71","author":"Beach","year":"2012","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"12","key":"10.1002\/14651858.CD010945.pub2-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013282.pub2","article-title":"Addenbrooke\u2019s Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment","author":"Beishon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/ijms10030724","article-title":"Molecular pathology of Lewy body diseases","volume":"10","author":"Beyer","year":"2009","journal-title":"International Journal of Molecular Science"},{"issue":"9","key":"10.1002\/14651858.CD010945.pub2-BIB0073|cit73","first-page":"Art. No.: MR000","article-title":"Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE","author":"Beynon","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/156720506779025242","article-title":"Pathways by which Abeta facilitates tau pathology","volume":"3","author":"Blurton-Jones","year":"2016","journal-title":"Current Alzheimer Research"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.wad.0000183086.99691.91","article-title":"Clinical features of frontotemporal dementia","volume":"19","author":"Boxer","year":"2005","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0076|cit76","unstructured":"Burns A O'Brien J Ames D Dementia Oxford University Press 2005"},{"issue":"3 pt 1","key":"10.1002\/14651858.CD010945.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.42.3.473","article-title":"Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers","volume":"42","author":"Chui","year":"1992","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0078|cit78","unstructured":"The Cochrane Collaboration Review Manager (RevMan) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in Alzheimer\u2019s disease drug development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"10","key":"10.1002\/14651858.CD010945.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010775.pub2","article-title":"Montreal Cognitive Assessment for the diagnosis of Alzheimer\u2019s disease and other dementias","author":"Davis","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0081|cit81","first-page":"99","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer's disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nature Reviews: Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0082|cit82","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Molecular Neurodegeneration"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurology"},{"issue":"11","key":"10.1002\/14651858.CD010945.pub2-BIB0084|cit84","first-page":"1119","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurolology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"6","author":"Dubois","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-171093","article-title":"A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer\u2019s disease","volume":"63","author":"Fantoni","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12874-019-0724-x","article-title":"Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies","volume":"19","author":"Freeman","year":"2019","journal-title":"BMC Medical Research Methodology"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0022-510X(65)90016-X","article-title":"The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics","volume":"2","author":"Hakim","year":"1965","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0089|cit89","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0090|cit90","article-title":"The pathobiology of vascular dementia","volume":"4","author":"Iadecola","year":"2013","journal-title":"Neuron"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.jacc.2019.04.034","article-title":"Vascular cognitive impairment and dementia","volume":"73","author":"Iadecola","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD010945.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1586\/ern.11.155","article-title":"Distinguishing Alzheimer's disease from other major forms of dementia","volume":"11","author":"Karantzoulis","year":"2011","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"100005","DOI":"10.1016\/j.bionps.2019.100005","article-title":"Diagnostic biomarkers of Alzheimer\u2019s disease: A state-of-the-art review","volume":"1","author":"Khoury","year":"2019","journal-title":"Biomarkers in Neuropsychiatry"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000505625","article-title":"An integrated view on vascular dysfunction in Alzheimer's disease","volume":"19","author":"Klohs","year":"2019","journal-title":"Neurodegenerative Diseases"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0096|cit96","unstructured":"Dementia UK Alzheimer's Society"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0301-0082(98)00091-4","article-title":"Brain shrinkage in alcoholics: a decade on and what have we learned?","volume":"58","author":"Kril","year":"1999","journal-title":"Progress in Neurobiology"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1530-0277.2009.01142.x","article-title":"Prevalence of alcohol-related problems in an elderly population and their association with cognitive impairment and dementia","volume":"34","author":"Lopes","year":"2010","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"6","key":"10.1002\/14651858.CD010945.pub2-BIB0099|cit99","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.53.6.1292","article-title":"Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias","volume":"53","author":"Lopez","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/jnnp.57.4.416","article-title":"Clinical and neuropathological criteria for frontotemporal dementia","volume":"57","author":"The Lund Manchester Groups","year":"1994","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1192\/bjp.180.2.144","article-title":"Dementia with Lewy bodies","volume":"180","author":"McKeith","year":"2002","journal-title":"British Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010945.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD010945.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD010945.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendation from the National Institute on Ageing and Alzheimer's Association workgroup","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the \u03b2-amyloid peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0109|cit109","unstructured":"National Institute of Clinical Excellence (NICE) Dementia: assessment, management and support for people living with dementia and their carers NICE 2018"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13760-017-0816-5","article-title":"Alzheimer\u2019s disease CSF biomarkers: clinical indications and rational use","volume":"117","author":"Niemantsverdriet","year":"2017","journal-title":"Acta Neurologica Belgica"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.0000000000000621","article-title":"Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative","volume":"83","author":"Noel-Storr","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0269881116680924","article-title":"Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology","volume":"31","author":"O'Brien","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD010945.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.54.5.1099","article-title":"Decreased \u00df-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"54","author":"Otto","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Molecular Neurodegeneration"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","article-title":"Applicability of current staging\/categorization of \u00e1-synuclein pathology and their clinical relevance","volume":"115","author":"Parkkinen","year":"2008","journal-title":"Acta Neuropathologica"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0117|cit117","first-page":"1","article-title":"Graphical enhancements to summary receiver operating characteristic plots to facilitate the analysis and reporting of meta-analysis of diagnostic test accuracy data","author":"Patel","year":"2020","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0118|cit118","unstructured":"Prince M Wimo A Guerchet M Ali GC Wu YT Prina M World Alzheimer Report 2015 The Global Impact of Dementia An analysis of prevalence, incidence, cost and trends Alzheimer's Disease International 2015 1 84"},{"issue":"9","key":"10.1002\/14651858.CD010945.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010079","article-title":"IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting","author":"Quinn","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010079.pub2","article-title":"Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations","author":"Quinn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"13","key":"10.1002\/14651858.CD010945.pub2-BIB0121|cit121","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.2000","article-title":"Association of Amyloid Positron Emission Tomography with Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD010945.pub2-BIB0122|cit122","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001893","article-title":"The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onsetAlzheimer's disease","volume":"2","author":"Ritchie","year":"2012","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0123|cit123","article-title":"Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementiaand other dementias in people with mild cognitive impairment (MCI)","volume":"6","author":"Ritchie","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1002\/14651858.CD010945.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","article-title":"Development of interventions for the secondary prevention of Alzheimer's dementia: the EuropeanPrevention of Alzheimer's Dementia (EPAD) project","volume":"3","author":"Ritchie","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010945.pub2-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010803.pub2","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementia in people with mild cognitive impairment (MCI)","author":"Ritchie","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp-2018-318944","article-title":"Models for dementia risk prediction: so much activity brings a need for coordination and clarity","volume":"90","author":"Ritchie","year":"2018","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0127|cit127","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-316844","article-title":"Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis","volume":"89","author":"Rizzo","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"h3029","DOI":"10.1136\/bmj.h3029","article-title":"Dementia: timely diagnosis and early intervention","volume":"350","author":"Robinson","year":"2015","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Roman GC Tatemichi TK Erkinjuntti T Cummings JL Masdeu JC Garcia JH Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 1993 43 2 250 60","DOI":"10.1212\/WNL.43.2.250"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fpubh.2018.00181","article-title":"Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies","volume":"6","author":"Ryan","year":"2018","journal-title":"Frontiers of Public Health"},{"issue":"12","key":"10.1002\/14651858.CD010945.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2044.2009.06141_14.x","article-title":"Tuohy needle can reduce the incidence of severe post dural puncture headache","volume":"64","author":"Sadashivaiah","year":"2009","journal-title":"Anaesthesia"},{"issue":"4","key":"10.1002\/14651858.CD010945.pub2-BIB0132|cit132","doi-asserted-by":"crossref","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","article-title":"Gamma-secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment","volume":"29","author":"Takami","year":"2009","journal-title":"J Neurosci"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Thomas VS Rockwood KJ Alcohol abuse, cognitive impairment, and mortality among older people Journal of the American Geriatrics Society 2001 49 4 415 20","DOI":"10.1046\/j.1532-5415.2001.49085.x"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"Van Everbroeck B Green AJ Pals P Martin JJ Cras P Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob Disease patients Journal of Alzheimer's Disease 1999 1 6 419 24","DOI":"10.3233\/JAD-1999-1606"},{"issue":"1","key":"10.1002\/14651858.CD010945.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.STR.27.1.30","article-title":"Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN)","volume":"27","author":"Wetterling","year":"1996","journal-title":"Stroke"},{"issue":"8","key":"10.1002\/14651858.CD010945.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0138|cit138","unstructured":"World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders World Health Organization 1993"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0139|cit139","unstructured":"World Health Organization Global surveillance, diagnosis, and therapy of human transmissible spongiform encephalopathies: report of WHO consultation World Health Organization 1998"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1041610209991001","article-title":"Trajectories of cognitive decline in Alzheimer\u2019s disease","volume":"22","author":"Wilkosz","year":"2010","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125317739818","article-title":"Frontotemporal dementia: latest evidence and clinical implications","volume":"8","author":"Young","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1002\/14651858.CD010945.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T04:49:40Z","timestamp":1634878180000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010945.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":142,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010945.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}